Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target
1,206 Followers
See the Price Targets and Ratings of:
See bloggers sentiment and opinion on ARWR
>ARWR Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARWR Stock 12 Months Forecast
Average Price Target
$58.43
▲(132.23% Upside)
| Highest Price Target$90.00 | Average Price Target$58.43 | Lowest Price Target$33.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
B.Riley Financial
Reiterated
Cantor Fitzgerald
Reiterated
Leerink Partners
―
Hold
―
Reiterated
SVB Securities Sticks to Its Hold Rating for Arrowhead Pharmaceuticals (ARWR)
Morgan Stanley
$40.00
Hold
58.98%
Upside
Reiterated
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Sarepta Therapeutics (NASDAQ: SRPT) and LivaNova (NASDAQ: LIVN)
SMBC Nikko
$80.00
Buy
217.97%
Upside
Initiated
SMBC Nikko Securities starts Arrowhead Pharma (ARWR) at OutperformSMBC Nikko Securities analyst David Hoang initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Outperform rating and a price target of $80.00.
Jefferies
$75.00
Buy
198.09%
Upside
Reiterated
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Jefferies
Unknown Analyst
Not Ranked
Bernstein
$27.00
Hold
7.31%
Upside
Reiterated
We are most interested to hear the company's plans in adipose tissue; if anything at R&D day is going to be a positive surprise for the stock, this will likely be it. At the prior earnings call, CEO Chris Anzalone stated that they had achieved over 90% silencing in NHPs with 6+ months duration. Our questions are mostly around delivery, localization, and safety. In pulmonary, we will see additional healthy volunteer data in ARO-RAGE including the highest dose (SAD but not MAD), and we will see healthy volunteer data for the first time in ARO-MUC5AC. As a reminder, Arrowhead presented impressive knockdown data for ARO-RAGE at the end of April (80% mean-max serum sRAGE reduction for those receiving 2 doses, Exhibit 3). Our expectations in MUC5AC are slightly lower. T olerability in asthma patients is an open question for us, but we won't see that until later in the year.
Best Analysts Covering Arrowhead Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy ARWR and Sell After:
1 Month
3 Months
1 Year
Success Rate
18/33 ratings generated profit
Average Return
+39.94%
reiterated a buy rating 23 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +39.94% per trade.
2 Years
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
ARWR Financial Forecast
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is $58.43.
What is ARWR’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 132.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a conensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s price target?
The average price target for Arrowhead Pharmaceuticals is $58.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $33.00. The average price target represents 132.23% Increase from the current price of $25.16.
The highest analyst price target is $90.00 ,the lowest forecast is $33.00. The average price target represents 132.23% Increase from the current price of $25.16.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.